Introduction
============

Studies have shown that dry mouth is a multi-factorial disease in which the saliva flow decreases, thereby resulting in not only mouth dryness, feelings of thirst, and difficulty in food ingestion but also dysgeusia, dental caries, periodontal disease, burning mouth, and reduced quality of life (QOL).^([@B1])^ Although the pathogenesis of this disease is not yet fully elucidated, its incidence increases with age. The disease has been reported to be more common in postmenopausal women.^([@B2])^ In addition, an *in vivo* mouse experiment demonstrated that ovariectomy resulted in decreased salivary secretion and that estrogen replacement ameliorated this decrease.^([@B3])^ Although feelings of thirst have been reported to improve upon estrogen replacement therapy (ERT) in patients with menopausal disorders,^([@B4])^ an alternative method to ERT has been sought due to concerns of the Women's Health Initiative (WHI) regarding the link between ERT and tumorigenesis.^([@B5])^

In recent years, oxidative stress has been proposed to play a role in accelerated aging^([@B6])^ and in the pathogenesis of Sjogren's syndrome (SS), which is characterized by severe mouth dryness in middle-aged females.^([@B7])^ Particular oxygen radicals, such as superoxides and peroxides, mediate apoptosis,^([@B8])^ thus causing oxidative damage to membrane lipids and proteins and reducing their function.^([@B9])^ Furthermore, pathophysiological mechanisms involving oxidative damage have been reported.^([@B10],[@B11])^

In addition, the various physiological effects of soybeans and a variety of soybean bioactive compounds have been investigated. Specifically, research on soy isoflavones has been undertaken, and estrogenic effects on bone metabolism and anti-cancer activity have been reported.^([@B12]--[@B15])^

Isoflavones are a subclass of flavonoids that are abundantly found in the pulse family, including soybeans, soy foods, and Japanese arrowroot, and exist in the glycoside or aglycone form. A total of 12 types of soy isoflavones are contained in soybean and soy germ (hypocotyl), including the aglycones (genistein, daidzein, and glycitein), three types of glycosides, and their acetyl and malonyl glycosides.^([@B16])^ Although many aglycones are contained in fermented soybean products, such as miso and fermented soybeans, the isoflavones found in soybean or soybean products are typically glycosides. After ingestion, isoflavone glycosides are hydrolyzed by salivary enzymes,^([@B17])^ enzymes found in the small intestinal mucosa,^([@B18])^ and β-glucosidases from *Enterobacteriaceae*, thereby generating isoflavone aglycones^([@B19],[@B20])^ that are absorbed in the intestine to exert their effects.

Although the binding capacity of aglycones to estrogen receptors (ERs) differs according to the test method employed, it is reported to be weaker than that of estrogen.^([@B21],[@B22])^ Because of structural similarities to estrogen, aglycones specifically combine with ERs (α and β) and demonstrate estrogenic effects.^([@B23],[@B24])^ ER-α, which is abundant in the female genitalia, is also abundant in mammary glands, the hypothalamus, endothelial cells, and vascular smooth muscle. ER-β is abundant in the prostate gland, ovary, lung, brain, blood vessels, bone,^([@B25])^ and salivary glands.^([@B26]--[@B28])^

In addition, isoflavones exhibit antioxidative properties and ameliorating effects against free radical-induced damage of cell membrane lipids, lipoproteins,^([@B29]--[@B33])^ and DNA.^([@B34]--[@B37])^ In this study, the effects of soy isoflavones on dry mouth patients are examined.

Materials and Methods
=====================

Evaluation of isoflavone effects in subjects
--------------------------------------------

Tablets containing 25 mg of isoflavones extracted from soy (aglycone equivalent, 23.6 mg) were provided by Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan). Fifteen patients of the Dry Mouth Clinic of Tsurumi University Dental Hospital were enrolled in this study. The subjects included one male and fourteen females, ranging in age from 49 to 81 years (67.9 ± 8.0 years; mean ± SD). All fifteen subjects with dry mouth had a salivary secretion of less than 10 ml, as determined by the stimulated saliva flow rate (gum test). Ten patients were assigned to the SS group, and the remaining five to the non-SS group (Table [1](#T1){ref-type="table"}). The diagnosis of SS was based on the diagnostic criteria.^([@B38])^ Patients who had a medical history of significant cardiovascular disease, significant pulmonary obstructive disease, gastrointestinal obstructive disease, epilepsy, or Parkinson's disease were excluded from the study. The enrolled subjects had subjective dry mouth that was attributable to various factors (e.g., SS, adverse medication effects, mental stress, and depression). All 15 subjects provided informed consent. Each participant consumed one test tablet per day. The evaluation of the effects was performed by measuring salivary secretion and by a self-completed questionnaire (15 questions about oral and eye conditions) before intake and after 1 and 2 months of isoflavone intake.

Preparation of saliva
---------------------

Tests were performed before intake and 1 and 2 months after oral intake of the isoflavone tablet. A piece of sterilized gauze was weighed before and after being chewed by a participant for 2 min (Saxon test). The difference between the two measurements (dry weight before chewing and wet weight after chewing) was regarded as the salivary secretion. The saliva samples were centrifuged at 10,000 rpm for 30 min and then passed through an ultrafiltration membrane (pore size, 0.22 µm).

Measurement of oxidative stress
-------------------------------

The filtered samples were subjected to an enzyme-linked immunosorbent assay for the measurement of the oxidative stress marker 8-hydroxy-2\'-deoxyguanosine (8-OHdG) and the lipid peroxidation markers hexanoyl-lysine (HEL) and propanoyl-lysine (PRL) using an anti-8-OHdG monoclonal antibody (N45.1; Institute for the Control of Aging, Shizuoka, Japan), an anti-HEL monoclonal antibody (Institute for the Control of Aging), and an anti-PRL monoclonal antibody (Healthcare Systems Inc., Aichi, Japan), respectively. The marker 8-OHdG in the sample was analyzed by an antibody chip^([@B39])^ that was developed by Healthcare Systems Inc. As an antigen, 8-OHdG-BSA was spotted and immobilized onto the chip. The sample was then applied to the chip with a specific monoclonal antibody against 8-OHdG.^([@B40])^ The chip was further treated with anti-mouse immunoglobulin antibody alkaline phosphatase labelled. The binding of the antibody was evaluated by chemiluminescence using CDP-Star. The amount of 8-OHdG was estimated by comparison with the standard curve of authentic 8-OHdG. HEL and PRL were tested in the same manner as 8-OHdG.

Measurement of isoflavones
--------------------------

The frozen saliva samples were thawed on ice. Three aliquots of saliva were transferred to sample tubes. The internal standard solution (genistein-*d*~4~, daidzein-*d*~4~, and equol-*d*~4~) was added to each saliva sample (400 µl) to obtain a concentration of 125 pmol/ml. After the addition of ascorbic acid (50 µl of 0.1% phosphoric acid), the samples were hydrolyzed in the presence of the enzyme (60 µg) in phosphate buffer (pH 5.3, 500 µl) for 2 h at 37°C. After hydrolysis, the isoflavones were extracted with ethyl acetate (1 ml) twice and concentrated using a centrifugal evaporator. The dried extract was redissolved in 20 µl of 20% acetonitrile containing 0.1% acetic acid. A portion (5 µl) of the solution was subjected to LC-MS/MS analysis. An HPLC system (SI-2, Shiseido, Tokyo, Japan) connected to a quadruple MS/MS system API 4000 Qtrap (AB SCIEX, Santa Clara, CA) was used, and data acquisition and mass spectrometric evaluation were conducted using Analyst 1.5.1 software (AB SCIEX). The HPLC gradient conditions were as follows: the ratio of methanol containing 0.1% acetic acid (solution B) was increased linearly against the 0.1% acetic acid (solution A) after 4 min from 20% to 60% over 11 min and then to 90% over 5 min with a flow rate of 0.3 ml/min on a Zorbax Eclipse XDB column (2.1 × 150 mm, 5 µm, Agilent Technologies, city, CA) at 40°C. Selected reaction monitoring (SRM) was used to perform mass spectrometric quantification of isoflavones (precursor ion to product ion transitions from *m/z* 241/119 for equol, *m/z* 245/123 for equol-*d*~4~, *m/z* 253/133 for daidzein, *m/z* 257/136 for daidzein-*d*~4~, *m/z* 269/133 for genistein, and *m/z* 273/136 for genistein-*d*~4~). The column eluent was introduced into the mass spectrometer using electrospray ionization in the negative-ion mode with a declustering potential of −90 V and ion spray voltage of --4,400 V. The temperature of the gas was 500°C. Nitrogen was used as the collision gas.

Statistical analysis
--------------------

The results are expressed as the mean ± SD. Two-way repeated measures ANOVA was performed to test for the main effects of group ("SS" or "non-SS"), time ("before intake" and "after intake"), and their interaction. These analyses were performed using IBM SPSS (Statistical Package for the Social Sciences) Statistics ver. 19 (IBM Japan Inc., Tokyo, Japan). The data were analyzed for statistical significance, and the significance level was set at *p*\<0.05.

Ethics
------

Informed consent was obtained from all subjects, and the Ethical Committee of Tsurumi University approved this study.

Results
=======

Saliva flow rate
----------------

The saliva flow rate results are shown in Table [2](#T2){ref-type="table"}. The Saxon test results showed a significant increase (*p* = 0.005) after 1 month (2.47 ± 1.66 g) and after 2 months (2.34 ± 1.65 g) compared with before intake (1.90 ± 1.50 g). No significant difference was found between the SS and non-SS groups.

Oxidative stress markers
------------------------

The oxidative stress results for the 8-OHdG, HEL, and PRL levels are shown in Table [3](#T3){ref-type="table"}. No significant differences were found among the measured data. For 8-OHdG, the comparison of the amount before intake (6.12 ± 7.79 ng/ml) with the amounts after 1 month (3.82 ± 3.21 ng/ml) and 2 months (3.87 ± 3.48 ng/ml) revealed an insignificant decrease. Meanwhile, HEL showed an insignificant decrease when the amount before intake (7.12 ± 8.35 ng/ml) was compared with that after 1 month (4.53 ± 5.83 ng/ml) or 2 months (4.71 ± 4.43 ng/ml). In general, the levels of 8-OHdG and HEL tended to decrease following intake. In contrast, for PRL, the comparison of the amount before intake (5.61 ± 9.92 ng/ml) with the amounts 1 month (8.86 ± 14.20 ng/ml) and 2 months (8.21 ± 13.36 ng/ml) after intake revealed an insignificant increase.

Isoflavone concentrations in saliva
-----------------------------------

The concentration of each isoflavone (daidzein, genistein, and equol) is shown in Table [4](#T4){ref-type="table"}. A significant main effect of time (after intake vs before intake) was noted for daidzein and genistein. Daidzein showed a significant increase when the amount before intake (32 ± 54 µmol) was compared with the amounts after 1 month (11 ± 9.8 µmol) and 2 months (45 ± 55 µmol), (*p* = 0.047). For genistein, a comparison of the amount before intake (47 ± 70 µmol) with the amounts 1 month (20 ± 22 µmol) and 2 months (64 ± 72 µmol) after intake revealed a significant increase (*p* = 0.034). For equol, a comparison of the amount before intake (0.27 ± 0.45 µmol) with the amounts after 1 month (0.48 ± 1.0 µmol) and 2 months (0.23 ± 0.53 µmol) revealed no significant difference. We speculate that the smaller than anticipated changes were due to the limits in the sensitivity of the employed tests.

Subjective measurements
-----------------------

The changes in the patient oral conditions are shown in Table [5](#T5){ref-type="table"}. The results of the two-way repeated measures ANOVA showed the interaction between two main factors (time and SS vs non-SS) on "dry mouth" (*p* = 0.031) and "need water during eating" (*p* = 0.020). The condition of the eye regarding eyestrain, blurriness, dryness, and eye ache is shown in Table [6](#T6){ref-type="table"}. No significant difference was found in any of the measured data.

Discussion
==========

In a human intervention clinical trial, isoflavones were shown to be effective in the prevention and relief of menopausal symptoms.^([@B41])^ Menopausal women with rapidly declining estrogen levels were reported to show decreased salivary secretion and intraoral discomfort.^([@B42]--[@B44])^ In addition, considering reports that ERs are found in the salivary glands and that estrogen itself is secreted in the saliva, decreasing estrogen levels are assumed to affect salivary secretion. Furthermore, menopausal women on hormone replacement therapy showed improvements in a number of oral health-related complaints, such as dry mouth, glossalgia, periodontal disease, oral stickiness, and dysgeusia.^([@B44],[@B45])^ In this study, a significant effect was observed in the amount of saliva; oxidative stress levels showed a decreasing trend, and the interaction between isoflavone intake and the presence of SS was confirmed regarding the items "dry mouth" and "need water when eating" by the intake of 25 mg of soybean isoflavones (23 mg as aglycone) per day for two months in 15 subjects who recognized dry mouth symptoms. Therefore, the intake of isoflavones was thought to be effective in the relief of dry mouth that occurs in menopause and SS and of the general physical complaints of SS-affected individuals who presented with serious dry mouth.

As a result of measuring these three oxidative stress items before and after intake, 8-OHdG and HEL showed decreased levels and indicated the possibility that oxidative stress was reduced and the amount of saliva was increased by the intake of isoflavones. With regard to the antioxidant effect of isoflavones, the potential that the saliva secretional capacity was activated by eliminating oxidative stress and that the amount of saliva increased by activating the water secretion mechanism can be considered as an effect is expected in the improvement of the salivary secretion capacity by the continuous intake of isoflavones.

Furthermore, in a human study of isoflavone supplementation, a significant improvement in blood flow was found.^([@B46])^ The components of saliva are derived from the blood and salivary glands, and the increase in salivary secretion was proposed to be due to "the increased blood flow". Thus, the possibility that the intake of isoflavones is useful for the recovery of salivary glands impaired by oxidative stress and for the improvement of blood flow is assumed in this study. Furthermore, the function of the salivary gland has likely been improved by the antioxidant effect of isoflavones against the oxidative stress of salivary glands, thereby improving the effect on blood flow. This potential mechanism may explain the significant promotion of saliva flow observed in our study. In the future, we aim to verify these results by analyzing the degree of the damage to salivary glands by oxidative stress and the direct effect of isoflavones on salivary glands.

With respect to the human intervention clinical trial, many effective cases found that the volume of isoflavone aglycones that should be ingested per day is at least 30 mg and that the ingestion period should be at least two weeks; in this study, the ingested amount was 25 mg, and the ingestion period was two months.^([@B47]--[@B50])^

The study by NIH reported that that "Isoflavone aglycone decreases the vasomotor symptom of menopause by 10--20%".^([@B51])^ With regard to this study, menopause symptoms, with a focus on "hot flash" symptoms, are thought to be improved by the intake of 30--60 mg of soy isoflavone aglycone per day for at least two weeks in the United States and Europe. A study evaluating the effects of isoflavones reported that differences in the metabolism of isoflavones by *Enterobacteriaceae* affected isoflavone potency.^([@B52],[@B53])^ Because intestinal bacterial flora differs among individuals as shown in previous studies and the average age of the subjects was older than 60 years, the potential change in bacterial flora is thought to be affected by increasing age and a decrease in the number of bacteria. Furthermore, approximately 50% of Asians are equol producers and contain the intestinal bacteria required to convert daidzein into equol, which may have affected the efficacy of this evaluation of isoflavones.^([@B54]--[@B58])^ Thus, we are planning to conduct the analysis with consideration of the equol-producing ability of individuals.

In this study, isoflavone intake is thought to act as an antioxidant in salivary glands impaired by oxidative stress, and the salivary function was likely improved by the increased blood flow. As the salivary secretion amounts of the subjects showed an increasing trend without any accompanying side effects, such as sweating and polyuria, which may be caused by salivary secretion promoters, an improvement in the QOL was confirmed. We aim to study the detailed mechanism in future studies.
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###### 

Characteristics for the subjects in this study

                         SS            Non-SS
  ---------------------- ------------- -------------
  Number of Subjects     10            5
  Sex (male/female)      1/9           0/5
  Age                    66.9 ± 9.4    69.8 ± 4.6
  Gum test (ml/10 min)   3.59 ± 2.31   6.28 ± 2.05
  Saxon test (g/2 min)   1.84 ± 1.56   2.01 ± 1.53

Values represent the mean ± SD. SS, Sjogren's syndrome; non-SS, dry mouth group.

###### 

Score for saliva flow rate pre- and post intake of isoflavones for dry mouth patients

  Item                   Before        After 1 month   After 2 months        Results of two-way repeated measures ANOVA                                   
  -------- ------------- ------------- --------------- --------------------- -------------------------------------------- ------- ------- ------- ------- ---------
  Saxon    Total         1.90 ± 1.50   2.47 ± 1.66     2.34 ± 1.65           Time                                         3.779   2.000   1.890   6.529   0.005\*
  SS       1.84 ± 1.56   2.10 ± 1.59   2.10 ± 1.72     Time × SS or non-SS   1.495                                        2.000   0.747   2.583   0.095   
  non-SS   2.01 ± 1.54   3.20 ± 1.71   2.84 ± 1.55     SS or non-SS          4.507                                        1.000   4.507   0.619   0.445   

Results of two-way repeated measures ANOVA. Values represent the mean ± SD. Total, all subjects; SS, Sjogren's syndrome group; non-SS, dry mouth group; \*Time, *p* \< 0.05.

###### 

Score for detection of oxidative stress in saliva pre- and post intake of isoflavones for dry mouth patients

  Item                            Before          After 1 month   After 2 months        Results of two-way repeated measures ANOVA                                       
  ---------------- -------------- --------------- --------------- --------------------- -------------------------------------------- -------- --------- -------- ------- -------
  8-OHdG (ng/ml)   Total          6.12 ± 7.79     3.82 ± 3.21     3.87 ± 3.48           Time                                         61.042   2.000     30.521   1.628   0.216
  SS               5.77 ± 7.03    4.19 ± 3.07     4.16 ± 3.79     Time × SS or non-SS   9.474                                        2.000    4.737     0.253    0.779   
  non-SS           6.83 ± 10.03   3.07 ± 3.73     3.29 ± 3.06     SS or non-SS          0.961                                        1.000    0.961     0.019    0.893   
  HEL (nmol/L)     Total          7.12 ± 8.35     4.53 ± 5.83     4.71 ± 4.43           Time                                         40.953   2.000     20.476   1.522   0.237
  SS               7.19 ± 9.11    3.79 ± 3.46     4.21 ± 3.46     Time × SS or non-SS   10.621                                       2.000    5.310     0.395    0.678   
  non-SS           6.96 ± 7.56    6.01 ± 9.37     5.72 ± 6.32     SS or non-SS          13.617                                       1.000    13.617    0.131    0.723   
  PRL (nmol/L)     Total          5.61 ± 9.92     8.86 ± 14.20    8.21 ± 13.36          Time                                         42.960   2.000     21.480   0.280   0.758
  SS               7.82 ± 11.66   12.82 ± 16.17   11.73 ± 15.35   Time × SS or non-SS   49.170                                       2.000    24.585    0.320    0.729   
  non-SS           0.35 ± 0.55    0.64 ± 1.21     0.31 ± 0.64     SS or non-SS          938.030                                      1.000    938.029   3.282    0.093   

Results of two-way repeated measures ANOVA. Values represent the mean ± SD. Total, all subjects; SS, Sjogren's syndrome group; non-SS, dry mouth group; 8-OHdG, 8-hydroxy-2\'-deoxyguanosine; HEL, hexanoyl-lysine; PRL, propanoyl-lysine.

###### 

Score for isoflavone concentrations in saliva pre- and post intake of isoflavones for dry mouth patients

  Item                             Before        After 1 month   After 2 months        Results of two-way repeated measures ANOVA                                             
  ------------------ ------------- ------------- --------------- --------------------- -------------------------------------------- ----------- ---------- ---------- ------- ---------
  Equol (µmol)       Total         0.27 ± 0.45   0.48 ± 1.00     0.23 ± 0.53           Time                                         1.148       2.000      0.574      0.418   0.664
  SS                 0.35 ± 0.55   0.64 ± 1.2    0.31 ± 0.64     Time × SS or non-SS   1.278                                        2.000       0.639      0.465      0.634   
  non-SS             0.13 ± 0.05   0.18 ± 0.10   0.07 ± 0.05     SS or non-SS          0.131                                        1.000       0.131      0.086      0.774   
  Daidzein (µmol)    Total         32 ± 54       11 ± 9.8        45 ± 55               Time                                         8775.315    2.000      4387.658   3.452   0.047\*
  SS                 41 ± 65       12 ± 11       40 ± 55         Time × SS or non-SS   2960.434                                     2.000       1480.217   1.165      0.328   
  non-SS             12 ± 18       9.7 ± 7.4     54 ± 61         SS or non-SS          383.663                                      1.000       383.663    0.102      0.755   
  Genistein (µmol)   Total         47 ± 70       20 ± 22         64 ± 72               Time                                         14901.865   2.000      7450.932   3.861   0.034\*
  SS                 63 ± 82       22 ± 25       59 ± 69         Time × SS or non-SS   6863.201                                     2.000       3431.601   1.778      0.189   
  non-SS             13 ± 15       15 ± 13       73 ± 84         SS or non-SS          1933.870                                     1.000       1933.870   0.285      0.603   

Results of two-way repeated measures ANOVA. Values represent the mean ± SD. Total, all subjects; SS, Sjogren's syndrome group; non-SS, dry mouth group; \*Time, *p* \< 0.05. Most of the equol scores were under the limit of detection.

###### 

Score for the subjective measurements of the oral condition pre- and post intake of isoflavones for dry mouth patients

  Item                                                   Before        After 1 month   After 2 months        Results of two-way repeated measures ANOVA                                        
  ---------------------------------------- ------------- ------------- --------------- --------------------- -------------------------------------------- -------- -------- -------- --------- -------
  Dry mouth                                Total         4.07 ± 1.44   4.00 ± 1.13     3.87 ± 1.06           Time                                         0.067    2.000    0.033    0.178     0.838
  SS                                       4.60 ± 1.26   4.30 ± 1.25   4.10 ± 1.20     Time × SS or non-SS   1.489                                        2.000    0.744    3.977    0.031\*   
  non-SS                                   3.00 ± 1.22   3.40 ± 0.55   3.40 ± 0.55     SS or non-SS          11.378                                       1.000    11.378   3.292    0.093     
  Have a cough or phlegm                   Total         2.33 ± 1.05   2.53 ± 1.19     3.47 ± 4.96           Time                                         23.022   2.000    11.511   1.506     0.240
  SS                                       2.30 ± 1.16   2.50 ± 1.18   2.30 ± 1.06     Time × SS or non-SS   25.689                                       2.000    12.844   1.681    0.206     
  non-SS                                   2.40 ± 0.89   2.60 ± 1.34   5.80 ± 8.56     SS or non-SS          15.211                                       1.000    15.211   1.420    0.255     
  Difficulty in chewing                    Total         2.67 ± 1.40   2.73 ± 1.16     2.60 ± 1.30           Time                                         0.089    2.000    0.044    0.100     0.906
  SS                                       2.80 ± 1.62   3.00 ± 1.25   2.80 ± 1.48     Time × SS or non-SS   0.267                                        2.000    0.133    0.299    0.744     
  non-SS                                   2.40 ± 0.89   2.20 ± 0.84   2.20 ± 0.84     SS or non-SS          3.600                                        1.000    3.600    0.860    0.371     
  Difficulty in swallowing                 Total         3.00 ± 1.41   3.07 ± 1.16     2.80 ± 1.37           Time                                         0.467    2.000    0.233    1.000     0.382
  SS                                       3.30 ± 1.57   3.40 ± 1.17   3.10 ± 1.52     Time × SS or non-SS   0.022                                        2.000    0.011    0.048    0.954     
  non-SS                                   2.40 ± 0.89   2.40 ± 0.89   2.20 ± 0.84     SS or non-SS          8.711                                        1.000    8.711    1.935    0.188     
  Difficulty in speaking                   Total         2.67 ± 1.35   2.80 ± 1.08     2.53 ± 1.19           Time                                         0.200    2.000    0.100    0.239     0.789
  SS                                       2.90 ± 1.52   3.00 ± 1.05   2.50 ± 1.27     Time × SS or non-SS   1.267                                        2.000    0.633    1.515    0.239     
  non-SS                                   2.20 ± 0.84   2.40 ± 1.14   2.60 ± 1.14     SS or non-SS          1.600                                        1.000    1.600    0.436    0.521     
  Worried about mouth or tooth condition   Total         3.40 ± 1.30   3.27 ± 1.49     2.87 ± 1.30           Time                                         1.867    2.000    0.933    2.220     0.129
  SS                                       2.60 ± 1.52   2.60 ± 1.82   2.20 ± 0.84     Time × SS or non-SS   0.089                                        2.000    0.044    0.106    0.900     
  non-SS                                   2.60 ± 1.52   2.60 ± 1.82   2.20 ± 0.84     SS or non-SS          11.378                                       1.000    11.378   2.648    0.128     
  Have tooth or mouth sensitivity          Total         3.13 ± 1.46   3.07 ± 1.28     2.60 ± 1.40           Time                                         1.800    2.000    0.900    2.265     0.124
  SS                                       3.40 ± 1.26   3.20 ± 1.14   2.70 ± 1.42     Time × SS or non-SS   0.467                                        2.000    0.233    0.587    0.563     
  non-SS                                   2.60 ± 1.82   2.80 ± 1.64   2.40 ± 1.52     SS or non-SS          2.500                                        1.000    2.500    0.485    0.498     
  Need water when eating                   Total         3.87 ± 1.25   3.87 ± 1.30     3.67 ± 1.18           Time                                         0.022    2.000    0.011    0.056     0.945
  SS                                       4.20 ± 1.32   4.20 ± 1.40   3.70 ± 1.34     Time × SS or non-SS   1.800                                        2.000    0.900    4.558    0.020\*   
  non-SS                                   3.20 ± 0.84   3.20 ± 0.84   3.60 ± 0.89     SS or non-SS          4.900                                        1.000    4.900    1.203    0.293     
  Mouth feels pasty                        Total         3.40 ± 1.30   3.33 ± 1.11     3.00 ± 1.31           Time                                         1.089    2.000    0.544    1.755     0.193
  SS                                       2.70 ± 1.49   2.90 ± 1.29   2.70 ± 1.34     Time × SS or non-SS   0.556                                        2.000    0.278    0.895    0.421     
  non-SS                                   3.60 ± 1.34   3.20 ± 1.10   3.20 ± 1.30     SS or non-SS          0.178                                        1.000    0.178    0.041    0.842     
  Painful tongue                           Total         2.80 ± 1.57   2.87 ± 1.41     2.80 ± 1.37           Time                                         0.000    2.000    0.000    0.000     1.000
  SS                                       2.70 ± 1.49   2.90 ± 1.29   2.70 ± 1.34     Time × SS or non-SS   0.356                                        2.000    0.178    0.937    0.405     
  non-SS                                   3.00 ± 1.87   2.80 ± 1.79   3.00 ± 1.58     SS or non-SS          0.278                                        1.000    0.278    0.044    0.838     
  Worried about bad breath                 Total         2.40 ± 1.06   2.53 ± 0.99     2.47 ± 0.99           Time                                         0.089    2.000    0.044    0.234     0.793
  SS                                       2.30 ± 0.95   2.50 ± 1.08   2.50 ± 1.08     Time × SS or non-SS   0.267                                        2.000    0.133    0.703    0.504     
  non-SS                                   2.60 ± 1.34   2.60 ± 0.89   2.40 ± 0.89     SS or non-SS          0.100                                        1.000    0.100    0.034    0.856     

Results of two-way repeated measures ANOVA. Values represent mean ± SD. Total, all subjects; SS, Sjogren's syndrome group; non-SS, dry mouth group; \*Time × SS or non-SS, *p* \< 0.05.

###### 

Score for subjective measurements of the eye condition pre- and post intake of isoflavones for dry mouth patients

  Item                           Before        After 1 month   After 2 months        Results of two-way repeated measures ANOVA                                   
  ---------------- ------------- ------------- --------------- --------------------- -------------------------------------------- ------- ------- ------- ------- -------
  Eyestrain        Total         3.13 ± 1.30   2.93 ± 1.39     3.00 ± 1.41           Time                                         0.622   2.000   0.311   1.411   0.262
  SS               3.10 ± 1.29   3.10 ± 1.52   3.10 ± 1.60     Time × SS or non-SS   0.622                                        2.000   0.311   1.411   0.262   
  non-SS           3.20 ± 1.48   2.60 ± 1.14   2.80 ± 1.10     SS or non-SS          0.544                                        1.000   0.544   0.099   0.758   
  Blurred vision   Total         2.87 ± 1.46   2.87 ± 1.60     2.87 ± 1.46           Time                                         0.067   2.000   0.033   0.183   0.834
  SS               3.00 ± 1.63   2.90 ± 1.73   3.10 ± 1.60     Time × SS or non-SS   0.600                                        2.000   0.300   1.648   0.212   
  non-SS           2.60 ± 1.14   2.80 ± 1.48   2.40 ± 1.14     SS or non-SS          1.600                                        1.000   1.600   0.236   0.635   
  Dry eye          Total         3.60 ± 1.40   3.47 ± 1.55     3.33 ± 1.45           Time                                         0.422   2.000   0.211   1.614   0.218
  SS               3.80 ± 1.48   3.70 ± 1.64   3.50 ± 1.51     Time × SS or non-SS   0.067                                        2.000   0.033   0.255   0.777   
  non-SS           3.20 ± 1.30   3.00 ± 1.41   3.00 ± 1.41     SS or non-SS          3.600                                        1.000   3.600   0.560   0.468   
  Eye pain         Total         2.60 ± 1.64   2.47 ± 1.55     2.33 ± 1.54           Time                                         0.600   2.000   0.300   0.727   0.493
  SS               2.70 ± 1.77   2.60 ± 1.58   2.50 ± 1.72     Time × SS or non-SS   0.067                                        2.000   0.033   0.081   0.923   
  non-SS           2.40 ± 1.52   2.20 ± 1.64   2.00 ± 1.22     SS or non-SS          1.600                                        1.000   1.600   0.225   0.643   

Results of two-way repeated measures ANOVA. Values represent the mean ± SD. Total, all subjects; SS, Sjogren's syndrome group; non-SS, dry mouth group.
